Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hyponatraemia Age: Adult Condition: Hypervolaemic or euvolaemic cases associated with Syndrome of Inappropriate Antidiuretic Hormone (SIADH) |
Dose: Oral – 15 mg Frequency: once daily Note: Initially 15 mg once daily, increase to 30 mg once daily after 24 hours. Dose may be adjusted up to maximum 60 mg once daily to achieve desired response. Maximum treatment duration: 30 days. |
|
Indication: Autosomal dominant polycystic kidney disease (ADPKD) Age: Adult |
Dose: Oral – 60 mg daily Frequency: twice daily in 2 divided doses (45 mg before breakfast and 15 mg after 8 hours) Note: Initial dose. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: No approved pediatric dosage available Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment Creatinine Clearance 10-79 mL/minute |
Dose: Not specified – No dosage adjustment required Note: No dosage adjustment required |
|
Condition: Renal impairment Creatinine Clearance less than 10 mL/minute or dialysis |
Dose: Not specified – Not recommended Note: Not recommended; drug effects on serum sodium levels are likely lost at very low levels of renal function |
Administration
- May be taken with or without food
- Avoid grapefruit juice
Side Effect
- Significant Hyperuricaemia
- gout
- polydipsia
- polyuria
- hypovolaemia
- dehydration
- hyperkalaemia
- nocturia
- pollakiuria
- hyperglycaemia
- increased ALT/AST
- bilirubin
- Rarely
- anaphylaxis
- Nausea
- dry mouth
- constipation
- diarrhoea
- Malaise
- fever
- weakness
- Increased creatinine
- Hypoglycaemia
- decreased appetite
- hypernatraemia
- Headache
- dizziness
- Pruritus
- ecchymosis
- Syncope
- orthostatic hypotension
- Osmotic demyelination
- hepatotoxicity
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, clarithromycin, diltiazem)
|
Increased plasma concentration
|
|
Strong CYP3A4 inducers (e.g. rifampicin, barbiturates)
|
Decreased plasma concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Anuria, Volume Depletion
|
Risk of severe dehydration
|
|
Hypernatraemia
|
Risk of sodium imbalance
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at below 25°C in a dry place, protected from light. Keep out of reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.